Overall, glaucoma affects one in 200 people aged 50 and younger, and one in ten over the age of 80. Many may be able to benefit from the PNT treatment.
Treatment Advances we currently have are not good enough, IMO! PNT Treatment is needed.
In recent years, there have been some exciting advances in glaucoma treatment.
Sep 2008 Micropulse Laser Trabeculoplasty (MLT)
Micropulse laser trabeculoplasty (MLT) provides the same IOP-lowering effects as argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) with less energy and inflammation than the earlier procedures. MLT uses a specific diode laser (IQ 810, Iridex) with a much longer pulse length than SLT, but the temperature rises slowly, because laser energy is delivered in short microbursts over an extended period of time (milliseconds versus nanoseconds for SLT). The micropulse helps to minimize the IOP spikes that can sometimes occur after a laser procedure.
Important note: This technology is still being evaluated by glaucoma treatment professionals. MLT appears promising as a new technology, but there is no long-term, or even moderate-term follow-up to determine safety and efficacy as compared to existing, proven laser treatments for glaucoma.
PR Newswire and BusinessWire News Sunridge International Inc SNDZ:OTC Bulletin Board Market Luis Tiant and Sunridge International Partner to Provide Medical Relief in Cuba: Former Star Pitcher for the Red Sox and Yankees Leads the Fight Against Glaucoma PR Newswire 10:17 AM ET Sunridge International (OTC Bulletin Board: SNDZ), an innovative developer of safe and noninvasive therapies for glaucoma, proudly announces its partnership with Luis Tiant and Scientific Social Solutions Charitable Foundation (S3) to provide medical relief in Cuba. Tiant, a Cuban native and former starting pitcher for the Boston Red Sox and New York Yankees, will work in conjunction with the Scientific Social Solutions Charitable Foundation and Ophthalmic International (www.oi-pnt.com), a wholly owned subsidiary of Sunridge, to help Cubans fight glaucoma.
Sunridge will send a medical team to Cuba to train doctors and treat patients, followed by a shipment of supplies to a distribution center to help patients after the team leaves the island. Glaucoma is the 2nd lea ding cause of blindness in Cuba, an issue Mr. Tiant will promote as the spokesperson for this charity drive.
Ophthalmic International has pioneered Pneumatic Trabeculoplasty (PNT), a two-minute, noninvasive, cost effective, alternative treatment for glaucoma. This treatment is ideal for Cuba and other countries' national health care systems because PNT is safe; and the treatment lasts 3-4 months before another round of care is necessary.
"I'm very excited about being a partner with Sunridge and Ophthalmic International in this medical relief program for Cuba. I know that glaucoma is an incredibly ser ious problem not only in Cuba but everywhere, and it is always good to be able to give something back," states Luis Tiant.
Credibility and Success Worldwide: Sunridge International in Action
Sunridge International continues to champion PNT and combat glaucoma. "We're extremely pleased with our involvement with Luis Tiant and this project. It will not only help the citizens of Cuba, but will most likely start a domino effect in the Caribbean, because of the fact that 'PNT' provides a safe, affordable and effective treatment for glaucoma patients everywhere," says G. Richard Smith, President and CEO of Sunridge International.
About Sunridge International
Headquartered in Fountain Hills, Arizona, Sunridge International (www.sunridgeint.com) is an innovative developer of Pneumatic Trabeculoplasty (PNT), a safe, noninvasive therapy for glaucoma. Through its wholly owned subsidiary, Ophthalmic International, the company manufactures a vacuum fixation device and a patented design suction ring for the treatment of open angle glaucoma.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.
Contact: Jeff Smith, +1-480-837-6165, firstname.lastname@example.org